Thermo Fisher Scientific (TMO, Financial) experienced a notable stock movement with a 0.76% increase in its share price, reaching $600.00 per share. Trading volume was reported at 384,819 shares with a turnover rate of 0.10% and a price fluctuation of 1.13%.
Recent financial reports reveal that Thermo Fisher Scientific achieved a revenue of $10.541 billion, a net profit of $1.548 billion, and earnings per share (EPS) of $4.05. The gross profit amounted to $4.344 billion, with a price-to-earnings (P/E) ratio standing at 37.21.
In terms of institutional ratings, 77% of the 30 participating brokerage firms recommend buying the stock, while 23% suggest holding it. No firm has advised selling the stock.
Within the life sciences industry, the overall growth was 0.48%. Notable performers included Mainz Biomed N.V., Bioaffinity Technologies Inc C/Wts 07/09/2027 (To Pur Com), and Bioaffinity Technologies, Inc., which saw substantial gains. Other active stocks were Applied Dna Sciences, Inc., Mainz Biomed N.V., and Endra Life Sciences Inc., with turnover rates of 12.43%, 12.10%, and 6.31%, respectively. Stocks with significant price swings included Mainz Biomed N.V., Bioaffinity Technologies Inc C/Wts 07/09/2027, and Bioaffinity Technologies, Inc., with volatility rates of 27.62%, 15.87%, and 15.42%.
Thermo Fisher Scientific specializes in the sale of scientific instruments and laboratory equipment, diagnostics consumables, and life sciences reagents. By the end of 2023, the company operated through four segments: analytical technologies (17% of sales), specialty diagnostic products (10%), life sciences solutions (23%), and laboratory products and services, including CRO services (54%).
